Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1276 to 1290 of 7680 results

  1. Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) (TA701)

    NICE is unable to make a recommendation on crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older because Pfizer withdrew its evidence submission.

    Technology appraisal guidance
    Published
    19 May 2021

    Sections for TA701

  2. Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

    Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    21 April 2021
    View recommendations

    Sections for TA689

  3. Avelumab for untreated metastatic Merkel cell carcinoma (TA691)

    Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults.

    Technology appraisal guidance
    Published
    21 April 2021

    Sections for TA691

  4. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)

    Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    17 February 2021
    View recommendations

    Sections for TA673

  5. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

    Technology appraisal guidance
    Last updated
    10 August 2017
    View recommendations

    Sections for TA190

  6. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing venous thromboembolism after hip or knee replacement surgery in adults.

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA157

  7. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA158

  8. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Last updated
    20 May 2024
    View recommendations

    Sections for TA155

  9. Routine antenatal anti-D prophylaxis for women who are rhesus D negative (TA156)

    Evidence-based recommendations on routine anti-D prophylaxis for women who are rhesus D negative.

    Technology appraisal guidance
    Published
    27 August 2008
    View recommendations

    Sections for TA156

  10. Guidance on the use of ultrasound locating devices for placing central venous catheters (TA49)

    Evidence-based recommendations on using ultrasound locating devices for placing central venous catheters into the internal jugular vein.

    Technology appraisal guidance
    Published
    4 October 2002
    View recommendations

    Sections for TA49

  11. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

    Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    15 November 2017
    View recommendations

    Sections for TA488

  12. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    22 November 2017
    View recommendations

    Sections for TA489

  13. Naltrexone–bupropion for managing overweight and obesity (TA494)

    Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

    Technology appraisal guidance
    Published
    12 December 2017
    View recommendations

    Sections for TA494

  14. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.

    Technology appraisal guidance
    Last updated
    12 September 2017
    View recommendations

    Sections for TA357

  15. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Published
    6 September 2017
    View recommendations

    Sections for TA474